S
Schrodinger
Computational drug designing for pharmaceutical and biotechnology research
About Schrodinger
Schrödinger operates a cutting-edge computational platform that supports the research initiatives of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Founded in 1990, the company is dedicated to advancing science and talent to enhance its platform. Schrödinger also engages in both wholly-owned and collaborative drug discovery programs across various therapeutic areas. The business model revolves around providing advanced computational tools and services to its clients, which include a diverse range of organizations in over 70 countries. Revenue is generated through software licensing, collaborative research agreements, and drug discovery partnerships.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1990
- Headquarters
- New York City, United States
- Listing
- IPO 2020
- Employees
- 1,003
- Open positions
- 8
- Dealroom signal
- 76.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Arts & Culture, AI Drug Discovery, Techbio Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 4 companies, latest May 2024
- Capital deployed
- $187M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2024 | $10M | — | Bill & Melinda Gates Foundation | ↗ |
| GRANTOther financing | Nov 2021 | $4.9M | — | Bill & Melinda Gates Foundation | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $235M | -8.3% | −$142M | -60.4% |
| 2025 | $256M | +23.3% | −$209M | -81.7% |
| 2024 | $208M | -4.2% | −$209M | -100.6% |
| 2023 | $217M | +19.7% | −$225M | -104% |
| 2022 | $181M | +31.2% | −$124M | -68.7% |
| 2021 | $138M | +27.6% | −$120M | -87% |
| 2020 | $108M | — | −$86M | -79.1% |
Growth signals
Latest recorded traffic for Schrodinger is 150K monthly website visits, down 6.3% over the last three months. Schrodinger's team grew 24.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ajax TherapeuticsNew York City, United StatesDeveloping targeted therapies for hematologic cancers through innovative cytokine signaling pathways
$2.3Bvaluation
Xtal BioStructuresUnited States
$6Mvaluation
Morphic TherapeuticWaltham, United StatesBiotechnology company developing a new generation of oral integrin therapies
$2.2Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Bill Gates
Cascade Investment
Scott Becker
Bill & Melinda Gates Foundation
Qiming Venture Partners
Baron Capital
WuXi AppTec
Invus
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Schrodinger on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Schrodinger’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.